Table 2 Baseline characteristics of patients and treated lesions after propensity score matching
Characteristics | TACE | SBRT | p value |
|---|---|---|---|
n = 70 | n = 35 | ||
Gender | 0.543 | ||
Male | 62 (88.6) | 29 (83.0) | |
Female | 8 (11.4) | 6 (17.0) | |
Age in years | 66.8 ± 9.9 | 69.0 ± 8.1 | 0.514 |
ECOG1 | 0.999 | ||
0 | 45 (64.3) | 23 (65.7) | |
1/2 | 25 (35.7) | 12 (34.3) | |
Etiology of liver disease | 0.999 | ||
Viral | 8 (11.4) | 4 (11.4) | |
Non-viral | 62 (86.6) | 31 (88.6) | |
Child Score | 6.4 ± 1.5 | 6.4 ± 1.3 | 0.952 |
Child A | 40 (57.1) | 19 (4.3) | 0.836 |
Child B | 30 (81.4) | 16 (45.7) | 0.836 |
Previous treatmenta | 2 (2.9) | 29 (83.0) | < 0.001 |
None | 68 (97.1) | 6 (17.1) | < 0.001 |
Surgery | 1 (1.4) | 8 (22.9) | 0.879 |
Sorafenib | 1 (1.4) | 1 (2.9) | 0.001 |
TACE | 0 | 28 (80.0) | < 0.001 |
Intrahepatic tumor expansion | 0.999 | ||
Oligonodular | 13 (18.6) | 6 (17) | |
Multifocal | 57 (81.4) | 29 (83) | |
BCLC2 | 0.999 | ||
B | 49 (70.0) | 24 (68.6) | |
C | 21 (30.0) | 11 (31.4) | |
Largest tumor diameter [cm] | 8.3 ± 4.1 | 8.4 ± 3.9 | 0.845 |
Segmental PVT4 | 21 (30.0) | 11 (31.4) | 0.999 |
Laboratory | |||
Platelets [103/μl] | 211 ± 157 | 183 ± 131 | 0.217 |
AST7 [U/l] | 98 ± 83 | 99 ± 66 | 0.742 |
ALT8 [U/l] | 69 ± 61 | 55 ± 40 | 0.280 |
Bilirubin [mg/dl] | 1.6 ± 1.5 | 1.8 ± 1.8 | 0.511 |
Albumin [g/dl] | 3.6 ± 0.7 | 3.4 ± 0.5 | 0.109 |
AFP15 [ng/ml] | 3255.4 ± 10,907.7 | 2279.8 ± 9386.5 | 0.435 |
Technical data TACE3 and SBRT5 | |||
TACE | |||
cTACE6 | 70 (100.0) | ||
Drug-eluting beads TACE | 0 | ||
Number of TACE sessions | 2 ± 1 | ||
Two TACE | 49 (70.0) | ||
Three TACE | 21 (30.0) | ||
SBRT | median (IQR14) | ||
Total prescribed dose (TD) | 45 (42–50) Gy | ||
EQD210,TD9 | 56 (54–83) Gy | ||
Dmax10 | 53 (50–57) Gy | ||
EQD210,Dmax11 | 82 (62–98) Gy | ||
Dmean,liver 12 | 17 (14–25) Gy | ||
EQD2Dmean,liver 13 | 20 (14–36) Gy | ||